Product image of Lenalidomide Aurobindo (Lenalidomide) supplied by GNH India

Lenalidomide Aurobindo

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Aurobindo (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Aurobindo, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in appropriate patient populations.

GNH India supplies Lenalidomide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy.
  • Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
  • Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients.
  • Mantle Cell Lymphoma: provides disease control in relapsed or refractory cases when combined with other agents.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4^CRBN E3 ubiquitin ligase complex, altering substrate specificity and leading to degradation of transcription factors such as Ikaros and Aiolos. This results in anti‑proliferative, anti‑angiogenic, and immunomodulatory actions that inhibit tumor growth and enhance immune‑mediated tumor cell clearance.

Side Effects

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: lowered platelet levels that may cause bruising.
  • Anemia: decreased red blood cell count leading to weakness.
  • Diarrhea: loose stools that can affect hydration.
  • Rash: skin irritation or erythema.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia: profound immune suppression with fever.
  • Serious infections: opportunistic or bacterial infections requiring hospitalization.
  • Secondary malignancies: emergence of new cancers.
  • Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.
  • Hypersensitivity reactions: anaphylaxis or severe skin reactions.

Precautions & Warnings

  • Lenalidomide requires careful monitoring and specific safety measures.
  • Pregnancy: contraindicated; drug is teratogenic (Category X).
  • Blood counts: monitor complete blood count regularly during therapy.
  • Thromboembolic risk: assess patient history and consider prophylactic anticoagulation.
  • Renal function: evaluate and adjust use in patients with impaired kidney function.
  • Drug interactions: review concomitant medications for potential interactions.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Lenalidomide can interact with several medication classes, requiring vigilance.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase lenalidomide exposure.
  • Anticoagulants (e.g., warfarin): heightened bleeding risk.
  • Live vaccines: risk of uncontrolled infection.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers: may reduce therapeutic effectiveness.
  • Immunosuppressants: increased susceptibility to infections.
  • NSAIDs: potential additive effect on platelet function.

Frequently Asked Questions

Lenalidomide Aurobindo is prescribed for multiple myeloma, myelodysplastic syndromes that carry the del(5q) chromosomal abnormality, and mantle cell lymphoma. In each case the drug works as part of a broader treatment regimen to control disease progression and improve patient outcomes.

Lenalidomide binds to the cereblon protein within the CRL4^CRBN E3 ubiquitin ligase complex, changing the complex’s substrate profile. This leads to the degradation of specific transcription factors, resulting in anti‑proliferative, anti‑angiogenic, and immunomodulatory effects that suppress tumor growth and enhance immune‑mediated tumor cell killing.

The dose of Lenalidomide Aurobindo is individualized by the prescribing clinician based on the specific indication, disease stage, renal function, and patient tolerance. Healthcare professionals determine the appropriate strength, schedule, and duration for each patient.

Lenalidomide is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It is contraindicated in pregnancy and should not be used by breastfeeding mothers, as it may be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug (IMiD) class, but lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy and stronger anti‑angiogenic activity. Clinical choice depends on the specific disease, prior therapy, and individual patient tolerance.

Lenalidomide Aurobindo should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Lenalidomide Aurobindo is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact dosing schedule—daily, weekly, or on a specific cycle—depends on the indication and the treating physician’s recommendation.

The most serious risks include severe neutropenia, thrombocytopenia, venous thromboembolism, serious infections, and rare secondary malignancies. Patients should be monitored closely for signs of infection, bleeding, or clot formation, and immediate medical attention is required if such events occur.

Lenalidomide Aurobindo is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose adjustments are made. It should also be avoided in patients receiving live vaccines due to the risk of infection.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT